In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

In weakly acid conditions, lipid A can be hydrolyzed to obtain monophosphoryl lipid A (MPL® [GSK and other]), a compound ... Here we describe cancer vaccine candidates using MPL adjuvant in ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

While uncertainty often casts a shadow on the Street, U.S. investors welcomed the presidential and congressional election results with a late-night surge that carried into this morning. The Dow Jones ...

Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...

With a rich background in brand positioning, Laura brings a wealth of strategic experience partnering with renowned organizations including Keurig Dr Pepper, Nestle, American Cancer Society, Merck, ...

The company and other pharma groups that have sold ranitidine products over the ... can cause several forms of cancer and other illnesses – which is disputed by GSK and other defendants, which ...

But earlier this month, GSK announced that it had agreed to pay as much as $2.2 billion to settle the majority of lawsuits in US state courts involving claims that Zantac caused cancer.

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... advanced or recurrent endometrial cancer. And Blenrep is now filed with ...